Abstract
Gene mutations that lead to decreased contraction of vascular smooth-muscle cells (SMCs) can cause inherited thoracic aortic aneurysms and dissections. Exome sequencing of distant relatives affected by thoracic aortic disease and subsequent Sanger sequencing of additional probands with familial thoracic aortic disease identified the same rare variant, PRKG1 c.530G>A (p.Arg177Gln), in four families. This mutation segregated with aortic disease in these families with a combined two-point LOD score of 7.88. The majority of affected individuals presented with acute aortic dissections (63%) at relatively young ages (mean 31 years, range 17-51 years). PRKG1 encodes type I cGMP-dependent protein kinase (PKG-1), which is activated upon binding of cGMP and controls SMC relaxation. Although the p.Arg177Gln alteration disrupts binding to the high-affinity cGMP binding site within the regulatory domain, the altered PKG-1 is constitutively active even in the absence of cGMP. The increased PKG-1 activity leads to decreased phosphorylation of the myosin regulatory light chain in fibroblasts and is predicted to cause decreased contraction of vascular SMCs. Thus, identification of a gain-of-function mutation in PRKG1 as a cause of thoracic aortic disease provides further evidence that proper SMC contractile function is critical for maintaining the integrity of the thoracic aorta throughout a lifetime.
Original language | English |
---|---|
Pages (from-to) | 398-404 |
Number of pages | 7 |
Journal | American Journal of Human Genetics |
Volume | 93 |
Issue number | 2 |
DOIs | |
State | Published - Aug 8 2013 |
Bibliographical note
Funding Information:The authors are extremely grateful to the families involved in this study, as well as the physicians and genetic counselors who aided in the collection of clinical data from the families (available in the Supplemental Data ). We would like to thank the National Heart, Lung, and Blood Grand Opportunity Exome Sequencing Project and its ongoing studies, which produced and provided exome variant calls for comparison: the Lung Cohorts Sequencing Project (HL-102923), the Women’s Health Initiative Sequencing Project (HL-102924), the Heart Cohorts Sequencing Project (HL-103010), the Broad Institute Sequencing Project (HL-102925), the GenTAC Registry Consortium (HHSN268200648199C and HHSN268201000048C), the Northwest Genomics Center Sequencing Project (HL-102926, D.A.N, M.J.R, and J.S.), and the Family Studies Project Team. We thank Z. Ren for technical assistance. The following sources provided funding for these studies: RO1 HL62594 (D.M.M.), P50HL083794-01 (D.M.M.), P01HL110869-01 (D.M.M.), UL1 RR024148 (University of Texas Health Science Center at Houston), the Vivian L. Smith Foundation (D.M.M.), the TexGen Foundation (D.M.M.), Richard T. Pisani funds (D.M.M.), RO1 GM090161 (C.K.), Groupements d’Intérêt Scientifique Maladies Rares (C.B.), PHRC AOM09093 (G.J.), PHRC AOM 10108 (C.B.), ANR 2010 BLAN 1129 from the French National Research Agency (G.J.), and the European Union 7 th Framework Program integrated project “Fighting Aneurysmal Disease” ( www.fighting-aneurysm.org ) (J.B.M.).
Funding
The authors are extremely grateful to the families involved in this study, as well as the physicians and genetic counselors who aided in the collection of clinical data from the families (available in the Supplemental Data ). We would like to thank the National Heart, Lung, and Blood Grand Opportunity Exome Sequencing Project and its ongoing studies, which produced and provided exome variant calls for comparison: the Lung Cohorts Sequencing Project (HL-102923), the Women’s Health Initiative Sequencing Project (HL-102924), the Heart Cohorts Sequencing Project (HL-103010), the Broad Institute Sequencing Project (HL-102925), the GenTAC Registry Consortium (HHSN268200648199C and HHSN268201000048C), the Northwest Genomics Center Sequencing Project (HL-102926, D.A.N, M.J.R, and J.S.), and the Family Studies Project Team. We thank Z. Ren for technical assistance. The following sources provided funding for these studies: RO1 HL62594 (D.M.M.), P50HL083794-01 (D.M.M.), P01HL110869-01 (D.M.M.), UL1 RR024148 (University of Texas Health Science Center at Houston), the Vivian L. Smith Foundation (D.M.M.), the TexGen Foundation (D.M.M.), Richard T. Pisani funds (D.M.M.), RO1 GM090161 (C.K.), Groupements d’Intérêt Scientifique Maladies Rares (C.B.), PHRC AOM09093 (G.J.), PHRC AOM 10108 (C.B.), ANR 2010 BLAN 1129 from the French National Research Agency (G.J.), and the European Union 7 th Framework Program integrated project “Fighting Aneurysmal Disease” ( www.fighting-aneurysm.org ) (J.B.M.).
Funders | Funder number |
---|---|
PHRC | AOM 10108, AOM09093 |
TexGen Foundation | RO1 GM090161 |
The University of Texas Health Science Center at San Antonio | |
Vivian L. Smith Foundation | |
Agence Nationale de la Recherche | 2010 BLAN 1129 |
Agence Nationale de la Recherche |
ASJC Scopus subject areas
- Genetics
- Genetics(clinical)